Compare Incyte Corporation (INCY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Materials Select Sector SPDR Fund — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while Materials Select Sector SPDR Fund trades at $49.42 (market cap $7.73B). The key difference: Incyte Corporation is far larger — about 3× Materials Select Sector SPDR Fund's market cap, and Materials Select Sector SPDR Fund is more actively traded (13,681,146 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| INCY | XLB | |
|---|---|---|
Market Cap | $22.85B | $7.73B |
Volume | 1,927,029 | 13,681,146 |
Sector | Health | — |
52-Week High | $129.93 | $53.67 |
52-Week Low | $83.80 | $42.23 |
Typical Hold Time | 33 Days | 70 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
XLB, the Materials Select Sector SPDR ETF, trades at $49.55, up 1.16% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The fund is heavily concentrated in chemicals (49% of assets) and faces cyclical pressures, with recent news highlighting sector volatility amid AI-driven infrastructure demand. Key support sits at $48, while resistance is at $50.
The outlook for XLB is cautious due to sector overvaluation concerns and bearish technicals. Opportunities lie in long-term infrastructure trends, but risks include economic sensitivity and high concentration. Investors should weigh cyclical exposure against potential growth from manufacturing and AI-related material demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
